- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Anatomical terminology.
Displaying page 1 of 1.
EudraCT Number: 2022-001237-37 | Sponsor Protocol Number: NL81058.041.22 | Start Date*: 2022-09-22 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||||||||||||
Full Title: SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high-intermediate risk endometrial cancer: a pilot study | ||||||||||||||||||||||||||||
Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with high/high-intermediate risk endometrial cancer. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000283-28 | Sponsor Protocol Number: IB_2013–01 | Start Date*: 2013-11-13 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Efficacy and Safety of PD-0332991 in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 study | |||||||||||||
Medical condition: Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001725-24 | Sponsor Protocol Number: CTKI258AIC02 | Start Date*: 2011-10-03 | |||||||||||
Sponsor Name:Novartis Pharma Services | |||||||||||||
Full Title: DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib | |||||||||||||
Medical condition: Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FI (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000842-36 | Sponsor Protocol Number: Version128May2019 | Start Date*: 2020-04-07 | |||||||||||
Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||
Full Title: A Polatuzumab Vedotin Containing Chemo-Immunotherapeutic Regimen in Patients with Diffuse Large B-Cell Lymphoma Unsuitable for Full Dose R-CHOP Therapy | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004957-62 | Sponsor Protocol Number: ET20-093 | Start Date*: 2021-09-09 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: Immunotherapy in MSI/dMMR Tumors in perioperative setting | ||
Medical condition: MSI/dMMR tumors or EBV+ gastric cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004787-20 | Sponsor Protocol Number: MED3-201601 | Start Date*: 2017-10-11 | |||||||||||
Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn | |||||||||||||
Full Title: An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over ... | |||||||||||||
Medical condition: Patients with resectable advanced stage HNSCC (T1–T4 N0-N2 M0) with intermediate risk (resection margins > 5 mm, no perineural invasion and no extracapsular evasion) for whom definite RT post surge... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003260-28 | Sponsor Protocol Number: KT-US-473-0133 | Start Date*: 2022-07-18 | |||||||||||
Sponsor Name:Kite Pharma, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | |||||||||||||
Medical condition: Relapsed and/or Refractory Follicular Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002654-21 | Sponsor Protocol Number: RHMCAN1219 | Start Date*: 2017-11-23 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY. | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma (most common type of non-Hodgkins lymphoma) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
